arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Prelude Therapeutics Incorporated

PRLD Health Care Biotechnology: Pharmaceutical Preparations
$3.63
▼ -0.6% Today
as of Oct 23, 16:51 ET
Last 30 days -20.92% Sep 14 → Oct 23
$3.10 $3.57 $4.05 $4.53 $5.00 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.63
High
$3.69
Low
$3.41
Volume
$288,576
Avg Vol
$699,293
Mkt Cap
$302M
P/E (TTM)
—
Beta
—
52w High
$6.83
52w Low
$1.17
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 9 items

Oct 23 · 03:02 MarketBeat
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
Oct 16 · 20:01 PR GlobeNewswire
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Oct 16 · 12:35 Zacks
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
▸ Show all 9 press releases & news Free account →

PRLD earnings at a glance

The options market is pricing a move of about ±67.0% after the report, a range of roughly $1.20 to $6.06 from today's $3.63. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±3.2% on average; after the most recent report on May 12, 2026 it moved -3.3%. That means options currently expect more movement than PRLD has typically delivered. PRLD beat the consensus EPS estimate in 4 of its last 4 reported quarters. Implied volatility is currently 6%. The share price of $3.63 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.17
$6.83
43% of range
Avg surprise (last 4)
+24.3%
Avg reaction (last 2)
-3.2%
0% positive
Latest IV / EM
567%
EM ±67.0% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.58$-0.47$-0.35$-0.24$-0.13 Actual $-0.58Actual $-0.54Actual $-0.45Actual $-0.42Actual $-0.46Actual $-0.43Actual $-0.42Est $-0.47Actual $-0.41Est $-0.45Actual $-0.26Est $-0.35Actual $-0.13Est $-0.27Actual $-0.14 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-22M$-13M$-3M$7M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.14 — — — — financials
Tue May 12, 2026Mar/2026 $-0.13 $-0.27 +51.9% +69.0% -3.3% earnings
Wed Nov 12, 2025Sep/2025 $-0.26 $-0.35 +25.7% — — earnings
Thu Aug 14, 2025Jun/2025 $-0.41 $-0.45 +8.9% — — earnings
Tue May 6, 2025Mar/2025 $-0.42 $-0.47 +10.6% — -3.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.43 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.46 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.42 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.54 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.58 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$6M$5M—$6M$0$0—$3M
Cost of revenue————————
Gross profit————————
Operating income$-15M$-14M—$-20M$-32M$-35M—$-34M
Net income$-14M$-10M—$-20M$-31M$-32M—$-32M
EPS (diluted)$-0.14$-0.13—$-0.26$-0.41$-0.42—$-0.43

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$26M$22M$35M$48M$26M$40M$12M$11M
Inventory————————
Total current assets$155M$85M$106M$58M$77M$102M$136M$156M
Total assets$189M$120M$141M$95M$115M$141M$176M$197M
Long-term debt————————
Total liabilities$56M$59M$73M$36M$39M$38M$44M$41M
Total equity$134M$60M$69M$59M$76M$103M$131M$156M

Implied volatility — last 90 days

113%313%512%712%912% Jun 07 — IV 284% · EM ±39.4%Jun 08 — IV 291% · EM ±38.4%Jun 09 — IV 506% · EM ±63.5%Jun 10 — IV 305% · EM ±36.1%Jun 11 — IV 528% · EM ±58.4%Jun 12 — IV 272% · EM ±27.8%Jun 15 — IV 287% · EM ±20.7%Jun 16 — IV 645% · EM ±38.1%Jun 17 — IV 881% · EM ±36.8%Jun 19 — IV 199% · EM ±44.0%Jun 22 — IV 244% · EM ±50.9%Jun 23 — IV 234% · EM ±47.9%Jun 24 — IV 175% · EM ±35.1%Jun 25 — IV 249% · EM ±48.8%Jun 26 — IV 200% · EM ±38.2%Jun 29 — IV 140% · EM ±24.8%Jun 30 — IV 120% · EM ±20.7%Jul 01 — IV 146% · EM ±24.4%Jul 02 — IV 164% · EM ±26.5%Jul 03 — IV 169% · EM ±26.5%Jul 06 — IV 134% · EM ±18.5%Jul 07 — IV 202% · EM ±26.7%Jul 08 — IV 203% · EM ±25.4%Jul 09 — IV 177% · EM ±20.9%Jul 10 — IV 259% · EM ±28.6%Jul 13 — IV 324% · EM ±27.0%Jul 14 — IV 441% · EM ±31.9%Jul 15 — IV 484% · EM ±28.6%Jul 16 — IV 912% · EM ±38.1%Jul 20 — IV 302% · EM ±71.4%Jul 21 — IV 194% · EM ±45.2%Jul 22 — IV 691% · EM ±158.1%Jul 23 — IV 239% · EM ±53.8%Jul 24 — IV 331% · EM ±73.1%Jul 27 — IV 332% · EM ±69.4%Jul 28 — IV 147% · EM ±30.1%Jul 29 — IV 143% · EM ±28.7%Jul 30 — IV 152% · EM ±29.7%Jul 31 — IV 142% · EM ±27.2%Aug 03 — IV 174% · EM ±30.8%Aug 04 — IV 225% · EM ±38.7%Aug 05 — IV 188% · EM ±31.4%Aug 06 — IV 155% · EM ±25.1%Aug 07 — IV 140% · EM ±21.9%Aug 10 — IV 157% · EM ±21.8%Aug 11 — IV 169% · EM ±22.4%Aug 12 — IV 181% · EM ±22.7%Aug 13 — IV 150% · EM ±17.7%Aug 14 — IV 171% · EM ±18.9%Aug 17 — IV 175% · EM ±14.7%Aug 18 — IV 373% · EM ±27.0%Aug 19 — IV 527% · EM ±31.1%Aug 20 — IV 847% · EM ±35.4%Aug 24 — IV 167% · EM ±34.8%Aug 25 — IV 161% · EM ±33.0%Aug 26 — IV 166% · EM ±33.2%Aug 27 — IV 159% · EM ±31.2%Aug 28 — IV 136% · EM ±26.1%Aug 31 — IV 113% · EM ±20.1%Sep 01 — IV 138% · EM ±23.7%Sep 02 — IV 215% · EM ±35.9%Sep 03 — IV 215% · EM ±34.8%Sep 04 — IV 158% · EM ±24.7%Sep 07 — IV 179% · EM ±24.7%Sep 08 — IV 150% · EM ±19.8%Sep 09 — IV 157% · EM ±19.6%Sep 10 — IV 168% · EM ±19.9%Sep 11 — IV 227% · EM ±25.1%Sep 14 — IV 287% · EM ±24.0%Sep 15 — IV 352% · EM ±25.4%Sep 16 — IV 455% · EM ±26.8%Sep 21 — IV 143% · EM ±29.8%Sep 22 — IV 113% · EM ±23.2%Sep 23 — IV 125% · EM ±24.9%Sep 24 — IV 214% · EM ±42.0%Sep 25 — IV 324% · EM ±61.9%Sep 28 — IV 217% · EM ±38.4%Sep 29 — IV 191% · EM ±32.8%Sep 30 — IV 367% · EM ±61.4%Oct 01 — IV 375% · EM ±60.7%Oct 02 — IV 418% · EM ±65.4%Oct 06 — IV 686% · EM ±90.6%Oct 07 — IV 563% · EM ±70.5%Oct 08 — IV 567% · EM ±67.0%

Sector peers

ABEO
Abeona Therapeutics Inc.
$286M $4.40-2.4%
INDP
Indaptus Therapeutics, Inc.
$282M $3.160.0%
BNTC
Benitec Biopharma Inc.
$334M $8.65+1.8%
BCYC
Bicycle Therapeutics plc
$261M $3.55-0.6%
AMRN
Amarin Corporation plc
$254M $11.79+2.4%
IFRX
InflaRx N.V.
$252M $1.56+0.7%

PRLD earnings FAQ

What is PRLD's expected move for earnings?

Options currently price a move of about ±67.0%, or $2.43 per share either way from $3.63.

How does PRLD stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.2%, up 0 times and down 2 times.

What is PRLD's implied volatility?

PRLD's at-the-money implied volatility is about 6% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in